Literature DB >> 4114813

Lymphocyte transformation in immunoproliferative disorders.

D Catovsky, P J Holt, D A Galton.   

Abstract

Lymphocyte transformation with phytohaemagglutinin (PHA) was studied in 30 patients with immunoproliferative disorders (lymphoproliferative and plasma cell disorders).Lymphocyte transformation at 3 days was reduced in the lymphoproliferative disorders (chronic lymphocytic leukaemia (CLL), well-differentiated (lymphocytic) follicular lymphoma (FLL) and Waldenström's macroglobulinaemia (WM)), and normal in the plasma cell disorders (myelomatosis, primary systemic amyloidosis, α-chain disease and benign monoclonal gammopathy) and in idiopathic cold haemagglutinin disease. A case of plasma-cell leukaemia with increased numbers of abnormal cells in the circulation also showed reduced transformation. It is suggested that the presence in the circulation of abnormal lymphocytes (or plasma cells) accounts for the results in CLL and FLL, WM and plasma-cell leukaemia. In WM a correlation was found between the activity of the disease (expressed by the levels of IgM paraprotein) and the degree of blast transformation.The long-term (28 days) in vitro survival of lymphocytes using subconcentrations of PHA was also studied in 7 patients. The cell populations (PHA-non-responsive) of CLL and FLL, but not of WM, had a good in vitro survival, resembling in this respect the normal PHA-responsive population of lymphocytes, but they remained PHA-non-responsive after 4 weeks' culture. It is speculated that in CLL the long survival in vitro of the PHA-non-responsive (leukaemic) population corresponds to their long life-span in vivo.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4114813      PMCID: PMC2008467          DOI: 10.1038/bjc.1972.22

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Heterogeneity of lymphocytes in chronic lymphocytic leukaemia.

Authors:  A E Thomson; M A Robinson; G Wetherley-Mein
Journal:  Lancet       Date:  1966-07-23       Impact factor: 79.321

2.  Plasma cell dyscrasias. Current clinical and biochemical concepts.

Authors: 
Journal:  Am J Med       Date:  1968-02       Impact factor: 4.965

3.  Chromosomes and transformation of lymphocytes in lymphoproliferative disorders.

Authors:  S D Lawler; C R Pentycross; B R Reeves
Journal:  Br Med J       Date:  1968-10-26

4.  Technique for lymphocyte transformation.

Authors:  C R Pentycross
Journal:  J Clin Pathol       Date:  1968-03       Impact factor: 3.411

5.  [The lymphocyte populations in chronic lymphoid leukemia and their response to splenic irradiation].

Authors:  M J Peckham; C Parmentier
Journal:  Rev Fr Etud Clin Biol       Date:  1968 Jun-Jul

6.  Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes.

Authors:  W Dameshek
Journal:  Blood       Date:  1967-04       Impact factor: 22.113

7.  The effect of heterologous antisera and rheumatoid factor on the synthesis of DNA and protein by human peripheral lymphocytes.

Authors:  L J Holt; N R Ling; D R Stanworth
Journal:  Immunochemistry       Date:  1966-09

8.  [Irradiation of the spleen and immunologic response of peripheral lymphocytes in chronic lymphocytic leukemias].

Authors:  G Astaldi; R Airö; G Costa; N Duarte
Journal:  Blut       Date:  1966-05

9.  The enhanced survival of human peripheral lymphocytes in vitro using subthreshold concentration of phytohemagglutinin.

Authors:  C K Naspitz; M Richter
Journal:  Blood       Date:  1967-09       Impact factor: 22.113

10.  Evaluation of therapy in chronic lymphocytic leukemia using in vitro lymphocyte transformation.

Authors:  A R Kagan; R E Johnson
Journal:  Radiology       Date:  1967-02       Impact factor: 11.105

View more
  1 in total

1.  Inhibition of normal lymphocyte transformation by plasma and lymphocyte factors in chronic lymphatic leukaemia.

Authors:  H B Tavadia; R B Goudie; W D Nicoll
Journal:  Clin Exp Immunol       Date:  1974-02       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.